These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28119604)

  • 1. 68 and FX2149 Attenuate Mutant LRRK2-R1441C-Induced Neural Transport Impairment.
    Thomas JM; Li T; Yang W; Xue F; Fishman PS; Smith WW
    Front Aging Neurosci; 2016; 8():337. PubMed ID: 28119604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.
    Li T; He X; Thomas JM; Yang D; Zhong S; Xue F; Smith WW
    PLoS One; 2015; 10(3):e0122461. PubMed ID: 25816252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
    Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
    J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
    Su YC; Qi X
    Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that the LRRK2 ROC domain Parkinson's disease-associated mutants A1442P and R1441C exhibit increased intracellular degradation.
    Greene ID; Mastaglia F; Meloni BP; West KA; Chieng J; Mitchell CJ; Gai WP; Boulos S
    J Neurosci Res; 2014 Apr; 92(4):506-16. PubMed ID: 24375786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.
    Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Madero-Pérez J; Gonnelli A; Drouyer M; Chartier-Harlin MC; Taymans JM; Bubacco L; Greggio E; Hilfiker S
    Hum Mol Genet; 2017 Jul; 26(14):2747-2767. PubMed ID: 28453723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein.
    Niu J; Yu M; Wang C; Xu Z
    J Neurochem; 2012 Aug; 122(3):650-8. PubMed ID: 22639965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
    Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
    Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
    Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O
    Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
    Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR
    Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model.
    Weng YH; Chen CY; Lin KJ; Chen YL; Yeh TH; Hsiao IT; Chen IJ; Lu CS; Wang HL
    Exp Neurol; 2016 Jan; 275 Pt 1():104-15. PubMed ID: 26363496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of protein phosphatase 2A as an interacting protein of leucine-rich repeat kinase 2.
    Athanasopoulos PS; Jacob W; Neumann S; Kutsch M; Wolters D; Tan EK; Bichler Z; Herrmann C; Heumann R
    Biol Chem; 2016 Jun; 397(6):541-54. PubMed ID: 26894577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 transport is regulated by its novel interacting partner Rab32.
    Waschbüsch D; Michels H; Strassheim S; Ossendorf E; Kessler D; Gloeckner CJ; Barnekow A
    PLoS One; 2014; 9(10):e111632. PubMed ID: 25360523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
    Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
    Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in the mouse.
    Giesert F; Glasl L; Zimprich A; Ernst L; Piccoli G; Stautner C; Zerle J; Hölter SM; Vogt Weisenhorn DM; Wurst W
    Neurobiol Dis; 2017 Sep; 105():179-193. PubMed ID: 28576705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2.
    Liu S; Cui B; Dai ZX; Shi PK; Wang ZH; Guo YY
    Curr Neurovasc Res; 2016; 13(2):115-20. PubMed ID: 26979073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β.
    Kawakami F; Shimada N; Ohta E; Kagiya G; Kawashima R; Maekawa T; Maruyama H; Ichikawa T
    FEBS J; 2014 Jan; 281(1):3-13. PubMed ID: 24165324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.